<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03116997</url>
  </required_header>
  <id_info>
    <org_study_id>17-207</org_study_id>
    <nct_id>NCT03116997</nct_id>
  </id_info>
  <brief_title>Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant</brief_title>
  <official_title>Randomized Controlled Assessor Blinded Clinical Trial of Sugammadex Versus Neostigmine /Glycopyrrolate for Reversal of Rocuronium Induced Neuromuscular Blockade: Time to Discharge From Post Anesthesia Care Unit and Patient Satisfaction With Recovery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two different medications (neostigmine/glycopyrrolate&#xD;
      and sugammadex) to see if one drug improves patient comfort regarding the return of muscle&#xD;
      strength after surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 7, 2017</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure Participants' Recovery Time Post-Surgery</measure>
    <time_frame>1 day</time_frame>
    <description>Determine whether SUG, as compared to NEO decreases time for patients to be ready for discharge from the PACU post-surgery.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Neuromuscular blockade reversed with neostigmine/gly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Neuromuscular blockade reversed with sugammadex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine+glycopyrrolate</intervention_name>
    <description>At the conclusion of surgery neuromuscular blockade reversed with neostigmine/glycopyrrolate</description>
    <arm_group_label>Neuromuscular blockade reversed with neostigmine/gly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>At the conclusion of surgery neuromuscular blockade reversed with sugammadex</description>
    <arm_group_label>Neuromuscular blockade reversed with sugammadex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients age 18 years of age or greater who are capable of giving consent&#xD;
&#xD;
          -  Undergoing surgical procedures of expected length 6 &lt;/= hours requiring NMB&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  History of documented anaphylaxis or contraindication to any of the study medications&#xD;
&#xD;
          -  Active coronary disease with a positive cardiac stress test&#xD;
&#xD;
          -  History of severe chronic obstructive pulmonary disease (COPD) defined as an FEV1 &lt;&#xD;
             50% of predicted&#xD;
&#xD;
          -  Serum Creatinine &gt;/= 2.0 mg/dL&#xD;
&#xD;
          -  Severe hepatic dysfunction accompanied by coagulopathy&#xD;
&#xD;
               -  Definition:&#xD;
&#xD;
               -  Known liver Disease AND&#xD;
&#xD;
               -  INR &gt; 1.5 (except for patients on anticoagulants) AND&#xD;
&#xD;
               -  Platelet count &lt;100,00/ul without other obvious cause&#xD;
&#xD;
          -  Chronic sustained release opioid for &gt; 2 weeks duration pre op (in the 30 days prior&#xD;
             to surgery)&#xD;
&#xD;
          -  Use of toremifene&#xD;
&#xD;
          -  Significant cognitive impairment or documented psychologic impairment&#xD;
&#xD;
          -  Myasthenia gravis or other neuromuscular disease&#xD;
&#xD;
          -  Patients who are not eligible for standard anesthetic induction, eg, those needing&#xD;
             rapid sequence induction or awake fiberoptic bronchial intubation.&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) Status &gt; 3&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>German Echeverry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2017</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neuromuscular blockade</keyword>
  <keyword>sugammadex</keyword>
  <keyword>SUG</keyword>
  <keyword>neostigmine</keyword>
  <keyword>NEO/GLYCO</keyword>
  <keyword>17-207</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

